Early detection of relapse and early therapeutic intervention: The benefits of Devyser NGS method for chimerism analysis
A better patient care is the final objective for Dr. Helena Devos and the team at Sint Jan’s...
Thank you for requesting one of our whitepapers.
Devyser and QIAGEN collaborate on pre-analytical workflow for fetal RHD screening
Fetal derived cell-free DNA (cfDNA) is a key analyte for determining fetal RHD status in plasma...
Approval of Devyser’s RHD product in Canada
Devyser is today announcing that its product for non-invasive fetal RHD testing has been granted...
Devyser Diagnostics AB publishes quarterly report for the period January to March 2023
“The first quarter of the year saw continued strong growth, record gross margin and the launching...